Quarterly report · Q3
3353.TEDINET S100PYK8
Period2022-03-01 → 2022-11-30
Filed2023-01-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥25.4bn | 2022-03-01 → 2022-11-30 | Cons. | Net sales |
| Revenue | ¥33.6bn | 2021-03-01 → 2022-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥25.2bn | 2021-03-01 → 2021-11-30 | Cons. | Net sales |
| Operating income | ¥706m | 2022-03-01 → 2022-11-30 | Cons. | Operating income |
| Operating income | ¥1.0bn | 2021-03-01 → 2021-11-30 | Cons. | Operating income |
| Ordinary income | ¥888m | 2022-03-01 → 2022-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.4bn | 2021-03-01 → 2022-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2021-03-01 → 2021-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥998m | 2022-03-01 → 2022-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.2bn | 2021-03-01 → 2021-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥597m | 2022-03-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥852m | 2021-03-01 → 2022-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥670m | 2021-03-01 → 2021-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥623m | 2022-03-01 → 2022-11-30 | Cons. | Profit loss |
| Net income | ¥694m | 2021-03-01 → 2021-11-30 | Cons. | Profit loss |
| Total assets | ¥28.0bn | at 2022-11-30 | Cons. | Assets |
| Total assets | ¥29.1bn | at 2022-02-28 | Cons. | Assets |
| Total assets | ¥29.6bn | at 2021-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥15.6bn | at 2022-11-30 | Cons. | Liabilities |
| Total liabilities | ¥17.2bn | at 2022-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥12.4bn | at 2022-11-30 | Cons. | Net assets |
| Net assets / equity | ¥11.9bn | at 2022-02-28 | Cons. | Net assets |
| Net assets / equity | ¥11.7bn | at 2021-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.6bn | at 2022-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥8.0bn | at 2022-02-28 | Cons. | Cash and deposits |
| EPS (basic) | ¥159 | 2022-03-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.34 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥226.92 | 2021-03-01 → 2022-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥178.38 | 2021-03-01 → 2021-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.15 | 2021-09-01 → 2021-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 42.3% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2022-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.7% | at 2021-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-11-30 | −¥744m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-11-30 | −¥744m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-11-30 | −¥557m |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥17.3bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥17.3bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥1.1bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥450,000 |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥35m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥2.9bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥2.2bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥742m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥29m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥142m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥140m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥1m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥92m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-03-01 → 2022-11-30 | ¥26.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-03-01 → 2022-11-30 | ¥25.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥744m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-03-01 → 2022-11-30 | ¥1.3bn |
| Reconciling Itemsreconciling | revenue | 2021-03-01 → 2021-11-30 | −¥808m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-03-01 → 2021-11-30 | −¥808m |
| Reconciling Itemsreconciling | segment profit | 2021-03-01 → 2021-11-30 | −¥518m |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2021-03-01 → 2021-11-30 | ¥17.0bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2021-03-01 → 2021-11-30 | ¥17.0bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2021-03-01 → 2021-11-30 | ¥1.1bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue | 2021-03-01 → 2021-11-30 | ¥5.9bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue external | 2021-03-01 → 2021-11-30 | ¥5.9bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue intersegment | 2021-03-01 → 2021-11-30 | ¥450,000 |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | segment profit | 2021-03-01 → 2021-11-30 | ¥225m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue | 2021-03-01 → 2021-11-30 | ¥2.9bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2021-03-01 → 2021-11-30 | ¥2.1bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2021-03-01 → 2021-11-30 | ¥806m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2021-03-01 → 2021-11-30 | ¥72m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue | 2021-03-01 → 2021-11-30 | ¥175m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue external | 2021-03-01 → 2021-11-30 | ¥174m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue intersegment | 2021-03-01 → 2021-11-30 | ¥1m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | segment profit | 2021-03-01 → 2021-11-30 | ¥98m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-03-01 → 2021-11-30 | ¥26.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-03-01 → 2021-11-30 | ¥25.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-03-01 → 2021-11-30 | ¥808m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-03-01 → 2021-11-30 | ¥1.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 366
| Item | Context | Value | Unit |
|---|---|---|---|
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding gain on reversal of advance received (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding gain on transfer of business (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |